渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIIB 渤健公司

休市中 04-10 16:00:00 EDT

172.97

-4.14

-2.34%

盘后172.97

+0.000.00%

19:23 EDT

最高177.97	最低172.32	成交量150.20万
今开177.97	昨收177.11	日振幅3.19%
总市值253.75亿	流通市值252.93亿	总股本1.47亿
成交额2.60亿	换手率1.03%	流通股本1.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":172.97,"timestamp":1775851200000,"preClose":177.11,"halted":0,"volume":1501973,"hourTrading":{"tag":"盘后","latestPrice":172.97,"preClose":172.97,"latestTime":"19:23 EDT","volume":178872,"amount":30945510.80223,"timestamp":1775863431662,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.02337530348371077,"floatShares":146226846,"shares":146702272,"eps":8.79,"marketStatus":"休市中","change":-4.14,"latestTime":"04-10 16:00:00 EDT","open":177.97,"high":177.97,"low":172.32,"amount":260453548.21453002,"amplitude":0.031901,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":8.79,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":685080000000,"exchange":"NASDAQ","adjPreClose":177.11,"preHourTrading":{"tag":"盘前","latestPrice":176.86,"preClose":177.11,"latestTime":"09:29 EDT","volume":90,"amount":15957.99,"timestamp":1775827799782,"change":-0.25,"changeRate":-0.001412,"amplitude":0.004461},"postHourTrading":{"tag":"盘后","latestPrice":172.97,"preClose":172.97,"latestTime":"19:23 EDT","volume":178872,"amount":30945510.80223,"timestamp":1775863431662,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9935970183525069,"impliedVol":0.3882,"impliedVolPercentile":0.672},"requestUrl":"/m/hq/s/BIIB/tweets","defaultTab":"tweets","newsList":[{"id":"1197564615","title":"Alloy与渤健达成合作：借助技术平台推进多个未公开靶点的反义疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1197564615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197564615?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:02","pubTimestamp":1775556134,"startTime":"0","endTime":"0","summary":"Alloy Therapeutics近日宣布与生物技术巨头渤健公司达成战略合作。根据协议内容，渤健将利用Alloy特有的技术平台，加速针对多个未公开靶点的反义寡核苷酸疗法研发进程。此次合作将充分发挥双方在药物研发领域的专业优势，通过平台化技术手段提升治疗方案的开发效率。\n反义疗法作为精准医疗的重要分支，通过特异性调节基因表达来治疗疾病。此次合作涉及的多个靶点虽未公开具体信息，但双方表示将聚焦于存在重大未满足临床需求的疾病领域。业内观察人士指出，这种平台化合作模式有望为创新疗法研发提供新的范式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B894F039.SGD","LU0320765992.SGD","LU0234570918.USD","BK4533","BK4585","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","BK4532","LU0889565916.HKD","BK4139","LU0109394709.USD","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149102155","title":"渤健公司同意以56亿美元收购Apellis Pharmaceuticals，股价跌至1月以来最低点，日内跌幅达7.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149102155","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149102155?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:33","pubTimestamp":1774963995,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）股价遭遇重挫，在宣布将以56亿美元收购Apellis Pharmaceuticals Inc.后，盘中跌幅一度扩大至7.7%，创下自今年1月以来的最低水平。此次收购协议引发市场对渤健公司财务负担和整合前景的担忧，投资者纷纷抛售股票，导致其股价承压下行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b2495f52240e7e9378faffff6c56a404","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4505","IE00B894F039.SGD","LU0320765992.SGD","LU0234570918.USD","IE00B19Z9P08.USD","BIIB","BK4533","LU1093756168.USD","LU0889565916.HKD","BK4139","BK4585","BK4588","IE00B19Z9Z06.USD","LU0109394709.USD","LU1093756325.SGD","APLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623858686","title":"Apellis(APLS)盘前涨超142% Biogen(BIIB)将以56亿美元收购该公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2623858686","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623858686?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:31","pubTimestamp":1774956713,"startTime":"0","endTime":"0","summary":"金吾财讯| Apellis Pharmaceuticals(APLS)盘前涨超142%，每股报41.05美元。消息面上，Biogen Inc.已同意以56亿美元收购Apellis Pharmaceuticals Inc.，扩大其在免疫学和罕见病领域的治疗能力，这是该公司有史以来规模最大的收购之一。该公司将以每股41美元的价格收购Apellis，是后者周一收盘价的两倍多。通过这笔交易，Biogen将获得两种已获批准的药物。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b2495f52240e7e9378faffff6c56a404","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298590","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0109394709.USD","LU0234570918.USD","LU0889565916.HKD","LU1093756325.SGD","IE00B894F039.SGD","LU0320765992.SGD","BK4139","BK4505","APLS","BK4585","BK4533","BIIB","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","BLLB","BK4532","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129135901","title":"渤健公司收购Apellis制药，强化免疫学与罕见病产品组合，提升增长前景并加速肾病领域扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=1129135901","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129135901?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:59","pubTimestamp":1774954764,"startTime":"0","endTime":"0","summary":"渤健公司宣布将收购Apellis制药公司，此举将显著增强其在免疫学和罕见病领域的增长型产品组合。通过这项战略收购，渤健公司不仅进一步巩固了其增长前景，还将加速向肾病治疗领域的业务扩张步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"586db16896b94a4fd80f4a5440e9e3f1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4588","IE00B19Z9Z06.USD","BK4533","BK4532","APLS","LU1093756168.USD","BK4585","LU0320765992.SGD","BIIB","LU0889565916.HKD","IE00B894F039.SGD","LU1093756325.SGD","LU0109394709.USD","LU0234570918.USD","IE00B19Z9P08.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166661258","title":"Biogen将以每股41美元现金加CVR（或有价值权）收购Apellis制药","url":"https://stock-news.laohu8.com/highlight/detail?id=1166661258","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166661258?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:55","pubTimestamp":1774954525,"startTime":"0","endTime":"0","summary":"3月31日，Apellis制药盘前飙升逾140%！Biogen将以每股41美元现金加CVR（或有价值权）收购该公司。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b2495f52240e7e9378faffff6c56a404","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Biogen将以每股41美元现金加CVR（或有价值权）收购Apellis制药","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLS","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144965019","title":"渤健公司：多数现有Spinraza患者无需承担额外自付费用——发言人表态","url":"https://stock-news.laohu8.com/highlight/detail?id=1144965019","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144965019?lang=zh_cn&edition=full","pubTime":"2026-03-30 22:34","pubTimestamp":1774881254,"startTime":"0","endTime":"0","summary":"渤健公司发言人近日明确表示，对于正在使用Spinraza（诺西那生钠注射液）的绝大多数现有患者，公司将确保其不会产生任何额外的自付医疗费用。这一承诺旨在缓解患者对治疗成本可能上涨的担忧，同时彰显企业对于保障治疗可及性的社会责任。\n据悉，该政策主要针对已稳定使用该药物的患者群体，通过内部成本调控与保险支付方案优化相结合的方式实现。Spinraza作为脊髓性肌萎缩症（SMA）的重要治疗手段，其费用保障机制对长期治疗患者具有显著意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0109394709.USD","LU0234570918.USD","LU0889565916.HKD","IE00B894F039.SGD","LU0320765992.SGD","BK4139","BK4585","BK4533","BIIB","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121301814","title":"渤健公司将以同等价格推出28毫克与12毫克药瓶，实现维持期患者平价用药","url":"https://stock-news.laohu8.com/highlight/detail?id=1121301814","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121301814?lang=zh_cn&edition=full","pubTime":"2026-03-30 22:33","pubTimestamp":1774881212,"startTime":"0","endTime":"0","summary":"渤健公司宣布将推出28毫克规格的药瓶，其定价与现有12毫克规格药瓶保持一致。这一举措意味着处于维持治疗阶段的患者能够以同等费用获得更多剂量的药物，真正实现用药成本平价化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","LU0320765992.SGD","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","BK4139","BK4533","LU0109394709.USD","BK4588","BK4585","LU0889565916.HKD","BK4532","IE00B894F039.SGD","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170377081","title":"渤健公司在2026年美国皮肤病学会年会公布利替利单抗治疗皮肤红斑狼疮二期试验再次取得积极结果，显示皮肤疾病活动显著降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1170377081","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170377081?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:01","pubTimestamp":1774724472,"startTime":"0","endTime":"0","summary":"渤健公司于2026年美国皮肤病学会年会上宣布，其研发的利替利单抗在针对皮肤红斑狼疮的第二项二期临床试验中再次获得积极数据。试验结果表明，该疗法能显著降低患者的皮肤疾病活动度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00B894F039.SGD","BK4139","BK4585","IE00B19Z9Z06.USD","BK4532","IE00B19Z9P08.USD","BK4533","LU0889565916.HKD","BK4588","LU0234570918.USD","BIIB","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179578414","title":"Alteogen与渤健公司就基于Hybrozyme™的皮下生物制剂达成开发与商业化授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1179578414","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179578414?lang=zh_cn&edition=full","pubTime":"2026-03-25 20:46","pubTimestamp":1774442785,"startTime":"0","endTime":"0","summary":"Alteogen公司（196170.KQ）宣布与渤健公司签署一项授权协议，共同开发及商业化基于Hybrozyme™技术的皮下注射生物制剂。\n根据协议条款，Alteogen将获得2000万美元的首付款，并在第二款产品进入开发阶段后收取1000万美元。针对协议中涉及的两款产品，Alteogen还有资格获得最高达5.49亿美元的里程碑付款。\n产品实现商业化后，Alteogen还将根据净销售额获得分层销售提成。此外，渤健公司保留在协议框架下开发第三款产品的选择权。\n该合作旨在利用Alteogen独有的Hybrozyme™平台技术，推动皮下给药型生物制剂的创新与发展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE00B19Z9P08.USD","IE00B894F039.SGD","LU0889565916.HKD","BK4533","BIIB","BK4585","BK4532","BK4139","BK4588","IE00B19Z9Z06.USD","LU0234570918.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146620422","title":"Leqembi®（Lecanemab-Irmb）在美国真实世界长期治疗持久性结果于Ad/Pd™ 2026公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1146620422","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146620422?lang=zh_cn&edition=full","pubTime":"2026-03-21 00:06","pubTimestamp":1774022772,"startTime":"0","endTime":"0","summary":"在Ad/Pd™ 2026会议上，渤健公司公布了Leqembi®（Lecanemab-Irmb）在美国真实世界长期治疗持久性的研究结果。该数据揭示了该药物在临床实践中的持续应用情况，为阿尔茨海默病治疗领域提供了重要参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00B894F039.SGD","BK4139","BK4585","IE00B19Z9Z06.USD","BK4532","IE00B19Z9P08.USD","BK4533","LU0889565916.HKD","BK4588","LU0234570918.USD","BIIB","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118349574","title":"渤健公司：所有接受Salanersen治疗的患者在一个或多个终点指标上均出现基线改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1118349574","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118349574?lang=zh_cn&edition=full","pubTime":"2026-03-11 20:03","pubTimestamp":1773230581,"startTime":"0","endTime":"0","summary":"根据最新临床试验数据显示，渤健公司研发的Salanersen药物在治疗过程中展现出积极效果。所有参与试验的患者在接受该药物治疗后，其病情评估指标均出现不同程度的改善。这些改善体现在一个或多个预设的临床终点指标上，且所有数据均以治疗前基线水平作为参照基准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","LU0320765992.SGD","BK4533","LU0889565916.HKD","IE00B19Z9P08.USD","IE00B894F039.SGD","BK4532","IE00B19Z9Z06.USD","BK4588","LU0234570918.USD","LU0109394709.USD","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609529234","title":"2025Q4| Vumerity逆势增长，Biogen销售额下滑好于分析师预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2609529234","media":"Minhua笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609529234?lang=zh_cn&edition=full","pubTime":"2026-02-07 15:54","pubTimestamp":1770450891,"startTime":"0","endTime":"0","summary":"2月6日，渤健公布2025年第四季度及全年业绩，整体销售额下滑7%至23亿美元，下滑主要因多发性硬化症  Tecfidera面临仿制药竞争后销售额暴跌51%。尽管Biogen预计其 2026 年的盈利预测将超出分析师预期，但该公司仍表示，由于其大部分 MS 产品持续面临压力，销售额将出现中等个位数的下滑。然而，Vumerity有望成为例外。2025年第四季度，Biogen整体销售额下滑7%至23亿美元，但高于分析师预测的22亿美元。Biogen寄希望于其在研产品线能够重回销售增长轨道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020715590995403dde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020715590995403dde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1244550577.SGD","LU0267386448.USD","LU0225283273.USD","LU1732800096.USD","IE00B894F039.SGD","BK4588","LU1668664300.SGD","LU2028103732.USD","IE00B19Z9Z06.USD","LU0106261372.USD","LU0158827948.USD","LU0528227936.USD","LU1791710400.SGD","BK4516","IE00BZ1G4Q59.USD","BK4585","LU2089284900.SGD","LU0557290698.USD","IE00BKVL7J92.USD","LU2111349929.HKD","LU0320765646.SGD","LU0098860793.USD","LU0314104364.USD","BIIB","LU0795875169.SGD","LU1363072403.SGD","BK4139","LU0158827781.USD","LU2023251221.USD","BK4127","LU0889565916.HKD","LU1244550221.USD","LU1244550494.USD","LU1720051017.SGD","LU1989772923.USD","LU0006306889.USD","LU0795875086.SGD","LU1791710582.SGD","BK4581","LU1074936037.SGD","BK4504","LU0971096721.USD","LU0234570918.USD","IE00B19Z9P08.USD","LU0320765992.SGD","BK4534","LU0882574139.USD","LU2089283258.USD","LU2271345857.HKD","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609597324","title":"渤健公司(BIIB)升4.34% 第四季业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2609597324","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609597324?lang=zh_cn&edition=full","pubTime":"2026-02-06 23:27","pubTimestamp":1770391629,"startTime":"0","endTime":"0","summary":"金吾财讯 | 渤健公司(BIIB)震荡扬升，截至发稿，升4.34%，报193.4美元。公司公布，去年第四季录每股盈利为1.99美元，高于之前预期的1.59美元；总营收23亿美元，亦高于预期的22亿美元。业绩指引方面，公司预计今年调整后每股盈利为15.25美元至16.25美元，高于市场预期的14.92美元。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/Mjg1NzQ1OGJhMDJiZWVjMjcxYjFlYjJjMTY3ODIxNTA4Njc=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Mjg1NzQ1OGJhMDJiZWVjMjcxYjFlYjJjMTY3ODIxNTA4Njc=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"296982","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4533","LU0889565916.HKD","IE00B894F039.SGD","BK4588","LU0234570918.USD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0320765992.SGD","BK4532","BIIB","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198005801","title":"异动解读 | 渤健公司盘中大涨5.13%，因年度利润超预期且展望积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1198005801","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198005801?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:59","pubTimestamp":1770389971,"startTime":"0","endTime":"0","summary":"渤健公司(BIIB)今日盘中大涨5.13%，引起了市场的广泛关注。消息面上，该公司公布的第四季度业绩及2026年利润展望均超出华尔街预期。其第四季度调整后每股收益为1.99美元，高于分析师平均预期的1.59美元；季度收入达23亿美元，亦高于预期。此外，公司预计2026年调整后每股利润将在15.25美元至16.25美元之间，高于市场预期的14.92美元。业绩超预期主要得益于其阿尔茨海默病治疗药物Leqembi等新药的需求增长，以及公司持续的成本削减措施。管理层表示，严格的费用纪律正在缓冲其多发性硬化症业务销售额下滑的影响，并对新药产品的增长抱有信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102477859","title":"渤健高管：公司将以最惠国视角推进欧洲新品上市 初期拟锁定三至四个国家","url":"https://stock-news.laohu8.com/highlight/detail?id=1102477859","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102477859?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:48","pubTimestamp":1770389299,"startTime":"0","endTime":"0","summary":"渤健公司高管近日透露，在欧洲市场推出新产品时，公司将采用最惠国待遇原则作为战略导向。据悉，初期计划优先选择三到四个国家作为试点市场，通过精细化布局逐步拓展欧洲业务版图。这种分阶段推进的策略既有助于控制风险，又能根据市场反馈动态调整商业部署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B19Z9Z06.USD","BK4533","BK4532","BK4585","LU0320765992.SGD","BIIB","LU0889565916.HKD","IE00B894F039.SGD","LU0109394709.USD","LU0234570918.USD","IE00B19Z9P08.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133804934","title":"渤健CEO称Leqembi口服剂符合D部分报销资格，但全额报销需等到2027年1月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804934","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133804934?lang=zh_cn&edition=full","pubTime":"2026-02-06 21:45","pubTimestamp":1770385515,"startTime":"0","endTime":"0","summary":"渤健公司首席执行官在电话会议中透露，其阿尔茨海默病治疗药物Leqembi的口服剂型已获得医疗保险D部分报销资格。不过，该药物要实现全额报销，必须等到2027年1月1日。\n这一时间表的设定，反映出医疗保险体系对新药报销审批流程的复杂性。虽然Leqembi口服剂已迈出关键一步，但患者要享受完整报销福利还需等待三年过渡期。\n此次披露的报销时间线，对渤健公司的市场战略和患者用药可及性都将产生深远影响。医药行业分析师指出，这一安排既体现了监管审慎，也为医疗支付体系适应创新疗法留出缓冲空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B19Z9Z06.USD","BK4533","BK4532","BK4585","LU0320765992.SGD","BIIB","LU0889565916.HKD","IE00B894F039.SGD","LU0109394709.USD","LU0234570918.USD","IE00B19Z9P08.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609859369","title":"“瘦身术”砍成本+押注阿尔茨海默病药等新药产品线 百健(BIIB.US)利润展望强于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2609859369","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609859369?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:33","pubTimestamp":1770381227,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百健公司于2月6日美股盘前公布2025年第四季度业绩以及未来业绩展望区间，最新数据显示，管理层给出的2026年利润展望高于华尔街分析师平均预期，这表明大幅削减成本的举措正在缓冲其多发性硬化症业务销售额萎缩带来的影响。过去12个月其股价已大幅上涨30%。维布拉赫表示，更广泛地使用血液检测来诊断阿尔茨海默病，也可能有助于扩大符合治疗条件的老年患者群体。美国监管机构的正式决定预计将在4月作出。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4533","BIIB","LU0234570918.USD","BK4532","BK4588","LU0320765992.SGD","BK4585","IE00B19Z9P08.USD","LU0109394709.USD","LU0889565916.HKD","IE00B19Z9Z06.USD","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164132348","title":"FDA优先审评受理Leqembi®（Lecanemab-Irmb）皮下起始剂量补充生物制剂许可申请，用于早期阿尔茨海默病治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1164132348","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164132348?lang=zh_cn&edition=full","pubTime":"2026-01-26 07:30","pubTimestamp":1769383838,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式受理渤健公司旗下Leqembi®（Lecanemab-Irmb）的补充生物制剂许可申请，将其皮下注射起始剂量方案纳入优先审评通道，用于治疗早期阿尔茨海默病。此次审评聚焦于该疗法在给药方式上的创新突破，有望为患者提供更便捷的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","LU0234570918.USD","IE00B19Z9Z06.USD","BK4139","LU0320765992.SGD","BK4533","BK4588","IE00B894F039.SGD","LU0889565916.HKD","BIIB","BK4532","LU0109394709.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603608825","title":"高盛：Leqembi与研发管线支撑增收增利结构性变革，给予百健(BIIB.US)“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2603608825","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603608825?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:10","pubTimestamp":1768468236,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛在与百健管理层会面后，给予其“买入”评级，目标价225美元。高盛表示，百健管理层强调了公司文化向专注于研发和费用控制的转变，这是其战略的一部分，旨在抵消多发性硬化症业务的下滑并推动增长。总而言之，高盛认为百健今年有望迎来转折点，这得益于研发管线催化剂和Leqembi的推动，以及严格的成本控制和优先发展早期罕见病和/或免疫学资产的合理业务发展策略。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"高盛：Leqembi与研发管线支撑增收增利结构性变革，给予百健(BIIB.US)“买入”评级","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133463005","title":"渤健公司预计第四季度支出2.22亿美元 每股盈利将受1.26美元冲击 股价应声下跌6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133463005","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133463005?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:24","pubTimestamp":1768404264,"startTime":"0","endTime":"0","summary":"渤健公司股价大幅下挫6%，此前该公司宣布预计第四季度将产生2.22亿美元的特殊支出。这笔一次性费用预计将使每股收益减少1.26美元，对当季盈利能力构成显著压力。\n市场对此消息反应迅速，投资者纷纷抛售股票，导致股价出现明显波动。此次支出预计将直接影响公司第四季度的财务表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4533","LU0889565916.HKD","BK4585","BIIB","BK4588","IE00B19Z9Z06.USD","IE00B894F039.SGD","LU0320765992.SGD","IE00B19Z9P08.USD","BK4532","LU0234570918.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biogen.com;investors.biogen.com","stockEarnings":[{"period":"1week","weight":-0.0246},{"period":"1month","weight":-0.0919},{"period":"3month","weight":-0.0781},{"period":"6month","weight":0.1801},{"period":"1year","weight":0.5256},{"period":"ytd","weight":-0.0172}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性生物制药公司，致力于为患有严重复杂疾病的人发现、开发和提供创新疗法。该公司拥有广泛的多发性硬化症（MS）药物组合，推出了首个获批治疗脊髓性肌萎缩症（SMA）的药物，共同开发了解决阿尔茨海默病定义病理学的治疗方法，并推出了首个获批的针对肌萎缩侧索硬化症（ALS）遗传原因的疗法。渤健还销售第一个也是唯一一个批准用于治疗16岁及以上成人和青少年的弗里德赖希共济失调（FA）的药物。其研发工作专注于神经病学、专业免疫学和罕见病，并得到内部项目、合作和收购的支持。该公司将生物制剂和生物仿制药商业化，并与领先的制药公司保持战略合作伙伴关系，以推进其产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.039226},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.00281},{"month":3,"riseRate":0.485714,"avgChangeRate":-0.023881},{"month":4,"riseRate":0.314286,"avgChangeRate":-0.022201},{"month":5,"riseRate":0.617647,"avgChangeRate":0.03339},{"month":6,"riseRate":0.470588,"avgChangeRate":0.016596},{"month":7,"riseRate":0.676471,"avgChangeRate":0.034715},{"month":8,"riseRate":0.588235,"avgChangeRate":0.030673},{"month":9,"riseRate":0.5,"avgChangeRate":0.023197},{"month":10,"riseRate":0.542857,"avgChangeRate":0.058896},{"month":11,"riseRate":0.6,"avgChangeRate":0.018187},{"month":12,"riseRate":0.457143,"avgChangeRate":0.034185}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}